Summary
Conclusion
the dossier summarised in one paragraphThe computed 12-month bankruptcy probability of AstraZeneca is 0.3% (very low). The 2025 annual accounts show equity of €46.88M and a net result of €8.65M. Equity is growing by ~8.7% per year across the filed fiscal years. Its solvency ranks better than 54% of 187 sector peers (fiscal year 2025). The company has been active since 1948 and the Belgian State Gazette contains no insolvency or warning signals.
Based on the State Gazette, CBE and 6 annual accounts.
Filing behaviour
From the deposit records, complete market-wideLatest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 17-06-2026, 44 days ahead of the deadline. This speaks to administrative punctuality and says nothing about the financial position.
The next deadline is still running
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today.
How we compute the deadline
The year end is derived from 10 filed financial years, each closing on 31-12. The statutory deadline is seven months after the close of the financial year (art. 3:10 par. 1 CAC, art. 3:47 par. 7 for ASBL and foundations). Applied to the financial year that closed on 31-12-2025, that is 31-07-2026.
Deadline per financial year
| Year closed | Due by | Filed | Variance | Reference |
|---|---|---|---|---|
| 31-12-2025 | 31-07-2026 | 17-06-2026 | 44 d early | 2026-00174284 |
| 31-12-2024 | 31-07-2025 | 23-06-2025 | 38 d early | 2025-00172821 |
| 31-12-2023 | 31-07-2024 | 17-07-2024 | 14 d early | 2024-00264743 |
| 31-12-2022 | 31-07-2023 | 21-06-2023 | 40 d early | 2023-00148600 |
| 31-12-2021 | 31-07-2022 | 24-06-2022 | 37 d early | 2022-20097104 |
| 31-12-2020 | 31-07-2021 | 15-06-2021 | 46 d early | 2021-21100127 |
| 31-12-2019 | 31-07-2020 | 31-07-2020 | on the day | 2020-38500526 |
| 31-12-2018 | 31-07-2019 | 11-07-2019 | 20 d early | 2019-32900054 |
| 31-12-2017 | 31-07-2018 | 05-06-2018 | 56 d early | 2018-16300442 |
| 31-12-2016 | 31-07-2017 | 26-06-2017 | 35 d early | 2017-23100126 |
Source: the National Bank's deposit records. Those records are complete, including for years whose figures we have not read yet. Filing late covers nearly half the market and is therefore not scored; only not filing, being more than 90 days late and breaking a punctual record carry weight.
Trust signals
2 signalsLong-established
Founded in 1948, 77 years in business.
No legal incidents
No bankruptcy, reorganisation or interim measure in the Belgisch Staatsblad, and the KBO register records a normal legal situation.
Administrative Flags
No strikeouts found in the KBO publications we processed. That series starts in 2021 and has gaps, so this is not a confirmation that there is nothing.
Bankruptcy probability (12 mo)
Checked model v1 · free for everyone0.3%
Very low
0%0,5%1,5%4%10%≥25%
Long track record
−Multiple establishment units
+Annual accounts: healthy financial profile
−
Statistical estimate based on public sources, not credit advice nor a finding of fact. How do we compute this?
Financials
Turnover€351.22M+26.0%
EBIT margin3.4%-0.3pp
Net result€8.65M-5.1%
Working capital€44.05M-30.0%
Annual accounts & ratios
Source: NBB · 2025Annual accounts filed on 17-06-2026 with the NBB · fiscal year 2025 · volledig
Trajectory (indicative)
Projection over 3 fiscal years from the filed annual accounts, not a forecast, the extended trend.
growing
Equity: growth of ~8.7%/year over 6 fiscal years, indicative, assuming unchanged policy.
Solid line = filed figures · dashed = extended trend · area = indicative range.
How do we compute this?
The trend is a robust median of all pairwise slopes between fiscal years (Theil-Sen), so a single odd year cannot hijack the line. For strictly positive series we also fit a log variant (compound annual growth) and keep whichever describes the figures best.
The area around the projection is 1.8 × the median absolute deviation from the trend, widening each year ahead (×1 / ×1.6 / ×2.2), with a minimum of 8% of the last value. It is an indicative range, not a statistical confidence interval.
A series whose deviations exceed 35% of its level is too volatile: we then deliberately show no projection. Every projection assumes unchanged policy and is blind to non-public information (order book, contracts, funding rounds).
Sector comparison
Fiscal year 2025 · NACE 46, Wholesale trade · compared within the same schema type (full schema)
| Metric | This company | Sector median | Position in the sector |
|---|---|---|---|
| Solvency | 44.5% | 41.5% | |
| Net result | €8.65M | €159k | |
| Equity | €46.88M | €1.10M | |
| Staff costs | €43.66M | €760k | |
| Employees (FTE) | 234.4 | 10.0 |
Median and position computed from NBB annual accounts filed by sector peers; own figures from the latest filed accounts.
Sector position over time
Percentile per fiscal year versus peers that filed figures, computed year by year (a year without enough peers is absent).
P54
Weakening position over 2020-2025
· n=187-597
P95
Stable position over 2020-2025
· n=187-596
P95
Stable position over 2020-2025
· n=187-597
P95
Stable position over 2021-2025
· n=142-446
Describes the position versus peers, not a forecast.
€351.22M
+26.0%
19-25
€12.13M
+17.6%
19-25
€8.65M
-5.1%
19-25
€8.80M
-3.8%
19-25
€105.38M
+12.0%
19-25
€46.88M
-25.6%
19-25
€44.05M
-30.0%
19-25
234
+10.8%
19-25
Show 14 other metrics
€43.66M
+13.8%
19-25
€3.24M
-8.4%
19-25
€0
-
19-25
€58.50M
+88.2%
19-25
€58.50M
+88.2%
19-25
1.75
-42.1%
19-25
1.75
-42.1%
19-25
44.5%
-33.6%
19-25
1.25
+153.1%
19-25
18.4%
+27.7%
19-25
8.2%
-15.2%
19-25
2.5%
-24.7%
19-25
3.5%
-6.7%
19-25
26.97
-31.7%
19-25
Figures by fiscal year
| Fiscal year | 2025 |
|---|---|
| Deposit | volledig |
| Revenue | €351.22M |
| EBITDA | €12.13M |
| Net profit | €8.65M |
| Cash flow | €8.80M |
| Staff costs | €43.66M |
| Income taxes | €3.24M |
| Dividends | €0 |
| Total assets | €105.38M |
| Equity | €46.88M |
| Debt | €58.50M |
| of which ≤ 1y | €58.50M |
| of which > 1y | - |
| Working capital | €44.05M |
| Employees (FTE) | 234.4 |
Ratios (computed)
| 2025 | |
|---|---|
| Current ratio | 1.75 |
| Quick ratio | 1.75 |
| Working capital ratio | 41.8% |
| Solvency | 44.5% |
| Debt / equity | 1.25 |
| Long-term debt ratio | - |
| Interest coverage | 26.97 |
| Gross margin | 60.8% |
| Net margin | 2.5% |
| ROA | 8.2% |
| ROE | 18.4% |
| EBITDA margin | 3.5% |
| Days sales outstanding | 56d |
| Days payable outstanding | 126d |
| Inventory turnover | - |
| Days inventory (DSI) | 0d |
Balance-sheet composition 2025
Full annual accounts (24 line items)
Filed balance sheet and income statement, exactly as deposited with the NBB.
| Line item | Code | 2025 |
|---|---|---|
| Balance sheet, Assets | ||
| TOTAL ASSETS | 20/58 | €105.38M |
| Fixed assets | 21/28 | €2.83M |
| Tangible fixed assets | 22/27 | €2.83M |
| Current assets | 29/58 | €102.56M |
| Stocks & contracts in progress | 3 | €0 |
| Amounts receivable within one year | 40/41 | €100.42M |
| Cash & bank | 54/58 | €1.48M |
| Balance sheet, Equity & liabilities | ||
| TOTAL EQUITY & LIABILITIES | 10/49 | €105.38M |
| Equity | 10/15 | €46.88M |
| Contributions / capital | 10/11 | €26.58M |
| Reserves | 13 | €2.79M |
| Accumulated profits (losses) | 14 | €17.51M |
| Provisions & deferred taxes | 16 | €0 |
| Amounts payable | 17/49 | €58.50M |
| Amounts payable within one year | 42/48 | €58.50M |
| Trade debts payable within one year | 44 | €47.38M |
| Income statement | ||
| Turnover | 70 | €351.22M |
| Operating result | 9901 | €11.99M |
| Financial income | 75 | €650k |
| Financial charges | 65 | €751k |
| Result before taxes | 9903 | €11.88M |
| Income taxes | 67/77 | €3.24M |
| Net result for the period | 9904 | €8.65M |
| Result to be appropriated | 9905 | €8.65M |
This table shows the latest fiscal year. 4 prior years, with figures and ratios, belong to a paid plan.
See plans →
Ratios computed by Checked.
Health barometer
FY 2025 · computed85
/ 100
Excellent
Computed from 6 of the 6 factors this model weighs. The rest cannot be derived from the filed figures, or need a prior year to compare against.
The full score breakdown, per-year score history and the indicative credit limit are in Kantoor S.
See plans →Computed by Checked from the NBB filing for FY 2025. Indicative, not credit advice.
Directors
Directors & mandates
26 directorsCurrent directors & mandates
-
Current21-02-2025 → present
2 events
- 21-02-2025 Appointed· Director
- 21-02-2025 Appointed· Managing director
-
Current21-09-2022 → present
4 events
- 30-04-2024 Resigned· Persoon belast met het dagelijks bestuur
- 30-04-2024 Resigned· Director
- 21-09-2022 Appointed· Director
- 21-09-2022 Appointed· Managing director
-
Current16-03-2022 → present
2 events
- 13-07-2022 Mandate renewed· Director
- 16-03-2022 Appointed· Director
-
Current29-09-2021 → present
3 events
- 13-07-2022 Mandate renewed· Director
- 19-10-2021 Appointed· Director
- 29-09-2021 Mandate renewed· Director
-
Current01-06-2019 → present
2 events
- 13-07-2022 Mandate renewed· Director
- 01-06-2019 Appointed· Director
Historic, not recently confirmed (5)
These mandates remain open in the register but have not been confirmed by a new act in over six years. They do not count as active directors.
-
Not recently confirmedlast confirmed in an act from 2014
-
Not recently confirmedlast confirmed in an act from 2013
2 events
- 01-09-2014 Resigned· Director
- 30-06-2013 Appointed· Director
-
Not recently confirmedlast confirmed in an act from 2009
-
Not recently confirmedlast confirmed in an act from 2009
-
Not recently confirmedlast confirmed in an act from 2006
Permanent representatives (2)
These people represent a legal-person director (a management company, for instance). They hold no board mandate of their own and do not count as directors.
-
Permanent representative31-12-2015 → present
-
Permanent representative- → 31-12-2015
Former directors (16)
-
Former01-06-2019 → 21-09-2022
4 events
- 21-09-2022 Resigned· Director
- 13-07-2022 Mandate renewed· Director
- 01-06-2019 Appointed· Managing director
- 01-06-2019 Appointed· Director
-
Former01-11-2019 → 03-09-2021
2 events
- 03-09-2021 Resigned· Director
- 01-11-2019 Appointed· Director
-
Former25-10-2018 → 01-11-2019
2 events
- 01-11-2019 Resigned· Director
- 25-10-2018 Appointed· Director
-
Former05-11-2015 → 01-06-2019
6 events
- 01-06-2019 Resigned· Director
- 04-10-2016 Mandate renewed· Director
- 01-01-2016 Appointed· Managing director
- 01-01-2016 Appointed· Director
- 05-11-2015 Appointed· Managing director
- 05-11-2015 Appointed· Director
-
Former01-06-2015 → 01-06-2019
3 events
- 01-06-2019 Resigned· Director
- 04-10-2016 Mandate renewed· Director
- 01-06-2015 Appointed· Director
11 further former directors in the mandate history. Available in Kantoor S.
See plans →
Full appointment history from the Belgian State Gazette. Permanent representatives are shown for corporate directors.
Statutory auditor
4 auditors| Statutory auditor | IRE/IBR number | Tenure |
|---|---|---|
| BV PwC Bedrijfsrevisoren Statutory auditor · represented by Romain Seffer |
- | 24-06-2020 → 24-06-2020 |
Show 3 earlier auditors
| Klynveld Peat Marwick Goerdeler Bedrijfsrevisoren Statutory auditor · represented by Filip De Bock succeeded by KPMG Réviseurs d'Entreprises in 2016 |
- | 23-06-2010 → 04-10-2016 |
| KPMG Réviseurs d'Entreprises Statutory auditor · represented by Raf Cox succeeded by BV PwC Bedrijfsrevisoren in 2020 |
- | 04-10-2016 → 24-06-2020 |
| PricewaterhouseCoopers Reviseurs d'Entreprises Statutory auditor · represented by Romain Seffer succeeded by BV PwC Bedrijfsrevisoren in 2020 |
- | 16-06-2017 → 24-06-2020 |
Appointed statutory auditor from the Belgian State Gazette. The IRE/IBR number refers to the register of the Institute of Registered Auditors.
Insolvency mandates
No insolvency mandates (liquidators, administrators) on record for this company.
Legal Structure
| NACE primary | Groothandel in farmaceutische en medische artikelen(46460) |
| Legal form | Public limited company(014) |
| Incorporation | 28-11-1948 |
| Status | Active |
| Postal code | 1702 |
Structure & network
Connections & network
14 connected companies8 further connections in this company's network. Available in Kantoor S.
See plans →Group structure
We sit on their board · 2 subsidiaries · 1 location
→
Network connections
Shared director
→
Shared director
→
Shared director
→
Shared director
→
Show 2 more network connections
Shared director
→
Shared director
→
7 further connected companies in this network. Available in Kantoor S.
See plans →
Connections derived from shared directors, addresses, shareholders and group structure in the Belgian State Gazette.
Ownership & control
1 partyAstraZenecaBE 0400.165.679
controls
Where this company holds controlthis company sits on their board1
2 subsidiaries · 1 location
Each band states what its claims rest on. A board seat is influence over the board, not ownership. Court mandates (receiver, interim administrator) and liquidation mandates do not link companies and are therefore absent here; they belong under Directors & mandates.
Locations & real estate
Registered office
from the Crossroads BankCannot be placed on the map
This address could not be matched to a point in the Belgian address register (BOSA BEST). The address below comes straight from the Crossroads Bank.
Alfons Gossetlaan 401702 DilbeekEstablishment units
3 locationsAlfons Gossetlaan 40, 1702 Dilbeek
since 20002.039.738.071
Rue André Dumont 5, 1435 Mont-Saint-Guibert
since 20252.386.236.721
Rue André Dumont 9, 1435 Mont-Saint-Guibert
since 20252.387.219.488
Physical sites registered in the Crossroads Bank for Enterprises (CBE).
Parcels1
Ground area4,478 m²
Buildings1
Building footprint1,360 m²
Volume (LiDAR)22,164 m³
Tallest building20.8 m · ±6 fl.
Real-estate footprint
Source: CBE × cadastre · address linkingParcels linked to this company through its CBE addresses (seat, establishment units, branches), cross-referenced with the cadastral parcel plan. This shows where the company operates, not a deeds register.
Flanders
1
(100%)
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 23026A0149/00M000 | Flanders | 4,477 m² | 1 · 1,360 m² | 20.8 m · 6 fl. |
Methodology
via registered seat: 1
1 of 1 parcels with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.
Publications
Lifecycle & Insolvency Signals
No insolvency signals in the Belgian State Gazette
Belgian State Gazette · acts
35 verified actsWhat every Belgian State Gazette publication actually says, each act broken down into appointments, capital movements, seat moves and statute amendments.
2025
04-04-2025
Resignations & appointments
- General meeting , 21/02/2025
- Board meeting , 25/02/2025
- Director appointment, Angela Thompson (bestuurder)
- Director appointment, Angela Thompson (gedelegeerd bestuurder)
- Mandate compensation, Angela Thompson
2024
05-08-2024
Resignations & appointments
- Board meeting , 15/05/2024
- Director resignation, Keira Driansky (bestuurder)
- Director resignation, Keira Driansky (persoon belast met het dagelijks bestuur)
2023
05-07-2023
Resignations & appointments
- General meeting , 26/05/2023
- Auditor appointment, PwC Bedrijfsrevisoren BV (commissaris)
- Permanent representative, Romain Seffer (vertegenwoordiger belast met de uitoefening van het mandaat)
2022
13-10-2022
Resignations & appointments
- General meeting , 21/09/2022
- Board meeting , 21/09/2022
- Director resignation, Anne-Laure Dréno (bestuurder)
- Director appointment, Keira Driansky (bestuurder)
- Mandate compensation, Keira Driansky
- Director resignation, Anne-Laure Dréno (persoon belast met het dagelijks bestuur)
+1 further fact
13-07-2022
Resignations & appointments
- General meeting , 19/05/2022
- Director reappointment, Anne-Laure Dréno (bestuurder)
- Director reappointment, Jennifer Olivero (bestuurder)
- Director reappointment, Luca Taliercio (bestuurder)
- Director reappointment, Paul Van Mullem (bestuurder)
- Mandate compensation, Anne-Laure Dréno
+4 further facts
Show 19 older acts
What every Belgian State Gazette publication actually says, each act broken down into appointments, capital movements, seat moves and statute amendments.
2022
07-04-2022
Resignations & appointments
- General meeting , 16/03/2022
- Director appointment, Jennifer Olivero (bestuurder)
- Director resignation, Nathalie Demeere
- Mandate compensation, Jennifer Olivero
- Director appointment, Luca Taliercio (bestuurder)
- Mandate compensation, Luca Taliercio
+2 further facts
2021
03-11-2021
Statutes amendment
- General meeting , 04-10-2021
- Statutes amendment
- Corporate purpose , in België en in het buitenland, ofwel voor zichzelf ofwel voor rekening van derden, alle verrichtingen in verband met de productie, de fabricage, de bereiding,…
- Capital , €22.000.000
19-10-2021
Resignations & appointments
- Board meeting , 29/09/2021
- Director resignation, Nathalie Demeere (bestuurder)
- Director appointment, Jennifer Olivero (bestuurder)
- Mandate compensation, Jennifer Olivero
2020
24-06-2020
Resignations & appointments
- Auditor appointment, BV PwC Bedrijfsrevisoren (commissaris)
- Permanent representative, Romain Seffer (vertegenwoordiger)
2019
05-12-2019
Resignations & appointments
- General meeting , 30/10/2019
- Director resignation, Lieve Wollaert (bestuurder)
- Director appointment, Nathalie Demeere (bestuurder)
- Power of attorney, NautaDutilh BVBA
17-06-2019
Resignations & appointments
- Board meeting , 09/05/2019
- General meeting , 29/05/2019
- Director resignation, Hervé Dussart (gedelegeerd bestuurder)
- Director resignation, Hervé Dussart (bestuurder)
- Director resignation, Valerie Buyse (bestuurder)
- Director appointment, Anne-Laure Dreno (persoon belast met het dagelijks bestuur)
+6 further facts
2018
25-10-2018
Resignations & appointments
- General meeting , 28/09/2018
- Director resignation, Leen Hofkens (bestuurder)
- Director appointment, Lieve Wollaert (bestuurder)
- Mandate compensation, Lieve Wollaert
31-05-2018
Registered office
- Board meeting , 07/05/2018
- Registered-office move , Alfons Gossetlaan 40 bus 201, 1702 Groot-Bijgaarden
- Establishment unit change , Alfons Gossetlaan 40 bus 201, 1702 Groot-Bijgaarden
2017
16-06-2017
Resignations & appointments
- General meeting , 24/05/2017
- Auditor appointment, KPMG Bedrijfsrevisoren BV CVBA (commissaris)
- Permanent representative, Raf Cox
- Director resignation, KPMG Bedrijfsrevisoren BV CVBA (commissaris)
- Auditor appointment, PricewaterhouseCoopers Bedrijfsrevisoren CVBA (commissaris)
- Permanent representative, Romain Seffer
2016
04-10-2016
Resignations & appointments
- General meeting , 27/05/2016
- Director reappointment, Leen Hofkens (bestuurder)
- Director reappointment, Valerie Buyse (bestuurder)
- Director reappointment, Hervé Dussart (bestuurder)
- Mandate compensation, Leen Hofkens
- Mandate compensation, Valerie Buyse
+4 further facts
29-04-2016
Resignations & appointments
- Board meeting , 14/03/2016
- General meeting , 18/03/2016
- Director resignation, Philippe Buée (gedelegeerd bestuurder)
- Director appointment, Hervé Dussart (gedelegeerd bestuurder)
- Director resignation, Philippe Buée (bestuurder)
- Director appointment, Hervé Dussart (bestuurder)
+1 further fact
11-04-2016
Resignations & appointments
- Board meeting , 14/03/2016
- General meeting , 18/03/2016
- Director resignation, Philippe Bué (gedelegeerd bestuurder)
- Director appointment, Hervé Dussart (gedelegeerd bestuurder)
- Director resignation, Philippe Bué (bestuurder)
- Director appointment, Hervé Dussart (bestuurder)
2015
20-11-2015
Resignations & appointments
- Board meeting , 27/10/2015
- Permanent representative, Filip DE BOCK
- Director resignation, Filip DE BOCK (vaste vertegenwoordiger)
- Permanent representative, Raf COX
- Director appointment, Raf COX (vaste vertegenwoordiger)
18-06-2015
Resignations & appointments
- Board meeting , 01/06/2015
- Director appointment, Valerie Buyse (bestuurder)
- Mandate compensation, Valerie Buyse
- Power of attorney, Anne Tilleux
08-04-2015
Resignations & appointments
- Board meeting , 17/03/2015
- Director appointment, Philippe Buée (persoon belast met het dagelijks bestuur)
04-03-2015
Resignations & appointments · Miscellaneous
- General meeting , 04/02/2015
- Director resignation, Christiane Wijsen (bestuurder)
- Director appointment, Philippe Buée (bestuurder)
- Mandate compensation, Philippe Buée
- Director resignation, Tarja Stenvall (bestuurder)
- Power of attorney, Anne Tilleux
+3 further facts
2014
03-11-2014
Resignations & appointments
- General meeting , 14/10/2014
- Board meeting , 14/10/2014
- Director resignation, Tarja Stenvall (bestuurder)
- Director resignation, Tarja Stenvall (gedelegeerd bestuurder)
- Power of attorney, Anne Tilleux
- Board composition , 2
+1 further fact
22-09-2014
Resignations & appointments
- General meeting
- Director resignation, Stéphane Gaullier (bestuurder)
- Director appointment, Chris Wijsen (bestuurder)
- Mandate compensation, Chris Wijsen
- Board composition , Confirmation of number of directors and their names
- Power of attorney, Anne Tilleux
+1 further fact
2013
06-09-2013
Resignations & appointments
- General meeting , 2013-05-31
- Director resignation, Piet Schutyser (bestuurder)
- Director reappointment, Leen Hofkens (bestuurder)
- Director reappointment, Tarja Stenvall (bestuurder)
- Mandate compensation, Leen Hofkens
- Mandate compensation, Tarja Stenvall
+12 further facts
Showing the 24 most recent of 35 acts. Full history
Analysis
Financial profile
5 of 5 axes measured77
/ 100
Exceptional profile, strong across almost every axis.
All 5 axes are computed from data Checked has read.
Health
85
Profitability
49
Solvency
84
Growth
68
Stability
100
Credit advice
verdict per customer and amountSimilar
Similar companies
Comparable size, same sectorBE 0459.093.476 · Machelen (Brab.)
BE 0802.868.505 · Watermaal-Bosvoorde
BE 0403.054.202 · Zaventem
BE 0406.820.770 · Watermaal-Bosvoorde
BE 0751.809.485 · Gent
We hold annual accounts for 199 of the 1,897 companies in this sector. 36 of them are within a factor 10 of this company's equity.
Company registry
Company registry (CBE)
Crossroads BankActivities
Groothandel in farmaceutische en medische artikelen46460
Primary activity highlighted.
Names & trade names
| Legal nameNL | AstraZeneca |
Registered office
Alfons Gossetlaan 40 bus 201
1702 Dilbeek, Belgium
Official data from the Crossroads Bank for Enterprises (CBE). Available for every registered company.